These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 25152580)
21. Personalising pancreas cancer treatment: When tissue is the issue. Sjoquist KM; Chin VT; Chantrill LA; O'Connor C; Hemmings C; Chang DK; Chou A; Pajic M; Johns AL; Nagrial AM; Biankin AV; Yip D World J Gastroenterol; 2014 Jun; 20(24):7849-63. PubMed ID: 24976722 [TBL] [Abstract][Full Text] [Related]
22. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407 [TBL] [Abstract][Full Text] [Related]
23. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562 [TBL] [Abstract][Full Text] [Related]
24. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727 [TBL] [Abstract][Full Text] [Related]
25. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. Macarulla T; Pazo-Cid R; Guillén-Ponce C; López R; Vera R; Reboredo M; Muñoz Martin A; Rivera F; Díaz Beveridge R; La Casta A; Martín Valadés J; Martínez-Galán J; Ales I; Sastre J; Perea S; Hidalgo M J Clin Oncol; 2019 Jan; 37(3):230-238. PubMed ID: 30523758 [TBL] [Abstract][Full Text] [Related]
26. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161 [TBL] [Abstract][Full Text] [Related]
28. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment. Sun H; Zhang B; Li H Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692 [TBL] [Abstract][Full Text] [Related]
29. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Ellenrieder V; König A; Seufferlein T Digestion; 2016; 94(1):44-9. PubMed ID: 27438590 [TBL] [Abstract][Full Text] [Related]
30. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Deplanque G; Demarchi M; Hebbar M; Flynn P; Melichar B; Atkins J; Nowara E; Moyé L; Piquemal D; Ritter D; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Hammel P Ann Oncol; 2015 Jun; 26(6):1194-1200. PubMed ID: 25858497 [TBL] [Abstract][Full Text] [Related]
31. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Sclafani F; Iyer R; Cunningham D; Starling N Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418 [TBL] [Abstract][Full Text] [Related]
32. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response. Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187 [TBL] [Abstract][Full Text] [Related]
33. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma. Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425 [TBL] [Abstract][Full Text] [Related]
34. Pancreatic biomarkers: could they be the answer? Lamarca A; Feliu J World J Gastroenterol; 2014 Jun; 20(24):7819-29. PubMed ID: 24976720 [TBL] [Abstract][Full Text] [Related]
35. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma. Stubbe BE; Madsen PH; Larsen AC; Krarup HB; Pedersen IS; Hansen CP; Johansen JS; Henriksen SD; Thorlacius-Ussing O Pancreatology; 2023 Aug; 23(5):512-521. PubMed ID: 37230892 [TBL] [Abstract][Full Text] [Related]
36. Update on the management of pancreatic cancer: surgery is not enough. Ansari D; Gustafsson A; Andersson R World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920 [TBL] [Abstract][Full Text] [Related]
37. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report. Ardalan B; Azqueta JI; England J; Eatz TA Cold Spring Harb Mol Case Stud; 2021 Oct; 7(5):. PubMed ID: 34667063 [TBL] [Abstract][Full Text] [Related]
38. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G Digestion; 2016; 94(4):222-229. PubMed ID: 28030863 [TBL] [Abstract][Full Text] [Related]